



Rick Doblin

**Rick Doblin, MAPS founder and President**, earned his Ph.D. in Public Policy from the Kennedy School of Government at Harvard University. Doblin was also in Stan and Christina Grof's first training group to receive certification as a Holotropic Breathwork practitioner.



Valerie Mojeiko

**Valerie Mojeiko, Director of Operations and Clinical Research Associate**, studied psychology with an emphasis on drug addiction and psychedelic therapy for four years at New College of Florida. Currently, she provides data monitoring services for MAPS-sponsored research and coordinates other projects.



Josh Sonstroem

**Josh Sonstroem, Technology Specialist and Events Coordinator**, earned his B.A. in Philosophy and Religion from New College of Florida and is a chef, musician, poet, technologist, and masseuse. He immensely enjoys the depths of existential experience.



Jag Davies

**Jag Davies, Director of Communications**, has a B.A. in cultural anthropology and enjoys examining the intersections of drug policy, media, culture and consciousness. He has been working at MAPS since 2003, where he coordinates outreach projects, research advocacy, and educational materials, including the MAPS Bulletin, monthly email news, and website content.



Sarah Hufford

**Sarah Hufford, Membership and Sales Manager**, joined the MAPS staff in the Fall of 2005, after receiving her bachelor's degree in psychology from New College of Florida. She values psychedelics and marijuana as powerful medicines, and hopes to help integrate their safe and conscientious use into our society.

## MAPS: Who We Are

MAPS IS A MEMBERSHIP-BASED ORGANIZATION working to assist researchers worldwide to design, fund, conduct, obtain governmental approval for, and report on psychedelic research in humans. Founded in 1986, MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax-deductible donations from members.

MAPS has previously funded basic scientific research in both humans and animals into the safety of MDMA (3,4-methylene-dioxymethamphetamine, Ecstasy) and has opened a Drug Master File for MDMA at the U.S. Food and Drug Administration. MAPS is now primarily focused on assisting scientists to conduct human studies to generate essential information about the risks and therapeutic benefits of MDMA, other psychedelics, and marijuana, with the goal of eventually gaining governmental approval for their medical uses.

ALBERT EINSTEIN WROTE:

*“Imagination is more important than knowledge.”*

If you can even faintly imagine a cultural reintegration of the use of psychedelics and the states of mind they engender, please join MAPS in supporting the expansion of scientific knowledge in this area. Progress is possible with the support of those who care enough to take individual and collective action.

### THE MAPS BULLETIN

Each Bulletin reports on MAPS research in progress. In addition to reporting on research both in the United States and abroad, the Bulletin may include feature articles, reports on conferences, book reviews, Heffter Research Institute updates, and the Hofmann Report. Issues raised in letters, calls, and e-mail from MAPS members may also be addressed, as may political developments that affect psychedelic research and use.

©2006 Multidisciplinary Association  
for Psychedelic Studies, Inc. (MAPS)  
10424 Love Creek Rd., Ben Lomond, CA 95005  
Phone: 831-336-4325  
Fax: 831-336-3665  
E-mail: [askmaps@maps.org](mailto:askmaps@maps.org)  
Web: [www.maps.org](http://www.maps.org)

